28 completed, 2 unknown. 30 Phase 2, 5 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 28, Unknown 2 |
| Phase 1 | 5 | Completed 4, Unknown 1 |
| Phase 3 | 5 | Completed 5 |
Follow Dry Eye Syndrome: new trials by email Literature Review of Dry Eye Syndrome trials Research Report on Dry Eye Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Probiotic in Dry Eye Syndromes Ophthalmic Probiotic, Opthalmic Placebo, Oral Probiotic Capsule - Dry Eye Syndrome | Phase 2 | Completed | Shiraz University of Medical Sciences | 40 | 2021-07-01 | 2023-03-27 |
| Treatment of Dry Eye Disease Using Pro-ocular™ - A Proof of Concept, Safety, and Efficacy Study Pro-ocular™ Topical Gel, Placebo Topical Gel - Dry Eye Syndrome, Keratoconjunctivitis Sicca | Phase 2 | Unknown | PharmaDax Inc. | 80 | 2021-05-20 | 2021-05-14 |
| A Study of the Drugs AGN-242428 and AGN-231868 in Participants With Dry Eye Disease AGN-242428, AGN-231868, AGN-242428 Vehicle - Dry Eye Disease, Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | AbbVie | 292 | 2020-03-04 | 2025-05-20 |
| Safety and Efficacy of BRM421 for Dry Eye Syndrome Treatment BRM421, Placebo - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | BRIM Biotechnology Inc. | 220 | 2020-01-15 | 2026-05-01 |
| Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome 0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS - Dry Eye Syndrome, Keratoconjunctivitis Sicca | Phase 2 / Phase 3 | Completed | Aurinia Pharmaceuticals Inc. | 508 | 2019-10-14 | 2021-12-10 |
| Safety, PK and Efficacy Study of SJP-0132 in Subjects With Dry Eye Disease SJP-0132, Placebo - Dry Eye Disease, Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Senju Pharmaceutical Co., Ltd. | 89 | 2019-10-05 | 2023-04-20 |
| A Study to Evaluate Safety and Efficacy of rhNGF Eye Solution vs Vehicle in Patients With Moderate to Severe Dry Eye rhNGF 20 μg/ml, rhNGF 20 μg/ml + vehicle, Vehicle - Dry Eye Syndrome | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 261 | 2019-06-10 | 2024-04-19 |
| Study of TOP1630 for Dry Eye Syndrome TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | Topivert Pharma Ltd | 202 | 2019-02-13 | 2019-08-07 |
| A Multi-Center, Randomized, Double Masked, Parallel-Group, Vehicle-Controlled, Clinical Study to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solution in Subjects With Dry Eye Disease Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.1%), Vehicle Ophthalmic Solution - Dry Eye Syndrome | Phase 2 | Completed | Aldeyra Therapeutics, Inc. | 300 | 2018-01-02 | 2025-02-06 |
| Clinical Study to Investigate the Efficacy and Safety of Orally Administered SA001 in Patients With Dry Eye Syndrome. SA001 Low dose, SA001 Mid dose, SA001 High dose - Dry Eye Syndrome | Phase 2 | Completed | Samjin Pharmaceutical Co., Ltd. | 172 | 2017-11-08 | 2022-03-18 |
| Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome AVX012 Ophthalmic Solution Low dose, AVX012 Ophthalmic Solution High dose, Placebo (vehicle) - Dry Eye Syndrome | Phase 1 / Phase 2 | Unknown | Avizorex Pharma, S.L. | 172 | 2017-04-03 | 2018-10-01 |
| Safety and Efficacy of TOP1630 for Dry Eye Syndrome TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution - Dry Eye Syndrome | Phase 2 | Completed | ORA, Inc. | 69 | 2017-02-20 | 2024-02-14 |
| Safety and Efficacy of BRM421 for Dry Eye Syndrome BRM421, Placebo - Dry Eye Syndrome | Phase 2 | Completed | BRIM Biotechnology Inc. | 157 | 2017-02-07 | 2026-05-01 |
| Efficacy and Safety Study of HU00701/HU007 Eye Drops in Patients With Dry Eye Syndrome HU00701, HU007, Restasis - Dry Eye Syndrome | Phase 2 | Completed | Huons Co., Ltd. | 114 | 2016-03-01 | 2018-04-12 |
| Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome: ARISE-1 RGN-259, Placebo - Dry Eye Syndrome | Phase 2 / Phase 3 | Completed | ReGenTree, LLC | 317 | 2015-09-01 | 2019-10-17 |
| Dose-finding Study to Assess the Safety and Effect of SYL1001 in Patients With Ocular Pain SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome | Phase 2 | Completed | Sylentis, S.A. | 66 | 2015-06-01 | 2016-04-05 |
| Phase 2 Study With Cis-UCA Ophthalmic Solutions in Subjects With Dry Eye cis-UCA ophthalmic solution 1.0%, cis-UCA ophthalmic solution 2.5%, Placebo ophthalmic solution - Dry Eye Syndrome | Phase 2 | Completed | Herantis Pharma Plc. | 161 | 2014-12-01 | 2015-09-09 |
| Safety and Efficacy of rhNGF Eye Drops at Different Doses in Patients With Dry Eye rhNGF 20 µg/mL, rhNGF 4 µg/mL - Dry Eye Syndrome | Phase 2 | Completed | Dompé Farmaceutici S.p.A | 40 | 2014-01-20 | 2024-04-19 |
| Safety and Efficacy of PG101 for Dry Eye Syndrome PG101 - Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Rhodes Pharmaceuticals, L.P. | 72 | 2013-12-01 | 2014-03-05 |
| Pilot Study to Evaluate SYL1001 Safety and Effect in Patients With Ocular Pain SYL1001, Placebo - Ocular Pain, Dry Eye Syndrome | Phase 1 / Phase 2 | Completed | Sylentis, S.A. | 60 | 2012-11-01 | 2015-05-25 |
Showing 20 of 30. Sign in to see all of them.
Dry Eye Syndromes (30) · Keratoconjunctivitis Sicca (4) · Eye Pain (2)
Eye Diseases (30) · Lacrimal Apparatus Diseases (30) · Conjunctival Diseases (4) · Conjunctivitis (4) · Corneal Diseases (4) · Keratitis (4) · Keratoconjunctivitis (4) · Eye Manifestations (2) · Neurologic Manifestations (2) · Pain (2) · Pathological Conditions, Signs and Symptoms (2) · Signs and Symptoms (2)
cenegermin (2) · isopropyl 5,12-hydroxypentadeca-8,10-dien-6,14-diynoate (2) · thymosin beta(4) (2) · Cyclosporins (1) · Gels (1) · Ophthalmic Solutions (1) · Probiotics (1) · lifitegrast (1) · recoflavone (1)
BRIM Biotechnology Inc. (2) · Dompé Farmaceutici S.p.A (2) · ReGenTree, LLC (2) · Sylentis, S.A. (2) · AbbVie (1) · Aldeyra Therapeutics, Inc. (1) · Aurinia Pharmaceuticals Inc. (1) · Avizorex Pharma, S.L. (1) · Bausch & Lomb Incorporated (1) · C.T. Development America, Inc. (1) · Dong-A ST Co., Ltd. (1) · Eyegate Pharmaceuticals, Inc. (1) · Gerhard Garhofer (1) · Herantis Pharma Plc. (1) · Huons Co., Ltd. (1)
United States (16) · South Korea (4) · Spain (3) · Austria (2) · Estonia (1) · Iran (1) · Mexico (1) · Taiwan (1) · United Kingdom (1)
Gail Torkildsen, MD (7) · John Lonsdale, MD (2) · Blair Boehmer, MD (1) · Choun-Ki Joo, M.D.,Ph.D. (1) · David Wirta, MD (1) · Eugene B McLaurin, MD (1) · Flavio Mantelli, MD, PhD (1) · G Torkildsen, MD (1) · Gail Torkildsen, M.D. (1) · Joel Geffin, MD (1)
PMID 27893109, PMID 30944103, PMID 33449860, PMID 33450164, PMID 37256485, PMID 39020305, PMID 42704415
2016 (1)